PMC:7696151 / 108621-109115
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
4055 | 72-80 | Species | denotes | patients | Tax:9606 |
4180 | 86-109 | Disease | denotes | chronic CHIKV infection | MESH:D007239 |
4181 | 435-439 | Disease | denotes | pain | MESH:D010146 |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T257 | 435-439 | Phenotype | denotes | pain | http://purl.obolibrary.org/obo/HP_0012531 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T740 | 0-494 | Sentence | denotes | Ravindran, et al. (2017) [28] Randomized controlled open-label study72 patients with chronic CHIKV infection 400 mg/day HCQ (n = 35)15 mg/day MTX, 1g/day sulfasalazine, and 400 mg/day HCQ (n = 37)34 weeks At the end of the 24th week, only the combination of drugs improved disease activity (mean ± SD DAS28; 3.39 ± 0.87 vs. 4.74 ± 0.65, p < 0.0001) and reduces disability (mean ± SD HAQ; 1.4 ± 0.31 vs. 1.8 ± 80.47, p < 0.0001) and pain (mean ± SD VAS 46 ± 6.13 vs. 60.8 ± 11.6, p < 0.0001). |